30th European Hematology Association Congress

• EHA •
• 15 June, 2025 •
• •

Real-world effectiveness of pacritinib in patients with myelofibrosis who have thrombocytopenia and anemia

Raajit Rampal, Samantha Eiffert, Michael Marrone, Lisa Morere, Abiola Oladapo, Anubhav Sharma, Purvi Suthar, Anupama Vasudevan, Michael Vredenburg , John Mascarenhas

Available materials

• EHA •
• 15 June, 2025 •
• •

Real-World Treatment Patterns and Clinical Outcomes in Patients with Myelofibrosis Treated with Pacritinib (PAC) with platelets ≥50 x10^9/L at PAC initiation: Interim results from the MY-PAC Study

Doug Tremblay, Abiola Oladapo, Emily Levine, Michael Marrone, Djibril Liassou, Purvi Suthar, Adina Geprifti, Gerard Hoehn, Michael Vredenburg , Bruce Feinberg, Naveen Pemmaraju, James Rossetti

Available materials

• EHA •
• 15 June, 2025 •
• •

Economic Burden of Cytopenia in Patients with Myelofibrosis: Analysis of a US National Administrative Claims Database

Aaron T Gerds, Lucia Masarova, Nicole M Engel-Nitz, Michael Marrone, Jefferey McPheeters, Abiola Oladapo, Purvi Suthar, Michael Vredenburg , Yong Zhu, Lindsay AM Rein

Available materials

• EHA •
• 14 June, 2025 •
• •

Benefit of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria irrespective of baseline transfusion status

Britta Höchsmann, Ana Boban, Marta Morado, Peter Hillmen, Sheena Patel, Johan Szamosi, Elena Surova, Jens Panse

Available materials

• EHA •
• 14 June, 2025 •
• •

A benefit assessment of pegcetacoplan dose increase in the Phase 3 PEGASUS trial of PNH patients with difficult-to-control disease

Morag Griffin, Alexander Röth, Brian Mulherin, Elena Surova, Regina Horneff, Peter Hillmen, Régis Peffault de Latour

Available materials

• EHA •
• 14 June, 2025 •
• •

Updated Safety Run-In Results From LOTIS-5: A Phase 3, Randomized Trial of Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Patients With R/R DLBCL/HGBL

Carmelo Carlo-Stella , Michal Kwiatek , Julien Depaus, Sebastian Grosicki, Sylvia Snauwaert, Edwin Kingsley, Javier López-Jiménez, Blanca Sanchez-Gonzalez, Andrzej Urban, Andrew Niewiarowski, Neus Domper-Rubio, Luqiang Wang, Eva Tiecke, Marie Toukam, Mehdi Hamadani

Available materials

• EHA •
• 14 June, 2025 •
• •

Initial Results from LOTIS-7: A Phase 1b Study of Loncastuximab Tesirine Plus Glofitamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Juan Pablo Alderuccio, Craig Okada, Gilles Crochet, Emily C. Ayers, Marie Hu, Silvia Ferrari, Paolo Caimi, Mehdi Hamadani, Julien Depaus, Enrico Derenzini, Jose Sandoval-Sus, Ruben Reyes, Andrzej Urban, Erica Rave, Eva Tiecke, Marie Toukam, Pier Luigi Zinzani

Available materials

• EHA •
• 14 June, 2025 •
• •

Effectiveness and Safety of Avatrombopag for Treatment of Immune Thrombocytopenia in Older Patients and Those with Comorbidities or Prior TPO-RA Exposure: Interim Results from the Phase 4 ADOPT Study

María Eva Mingot Castellano, María Teresa Álvarez Román, María Luisa Lozano, Wolfgang Miesbach, Hafiz Qureshi, Vickie McDonald, Jessica Zhang, Viridiana Cano Garcia, Nina Skuban, Waleed Ghanima

Available materials

• EHA •
• 14 June, 2025 •
• •

Effectiveness and Safety of Avatrombopag for the Treatment of Adults With Newly Diagnosed, Persistent, or Chronic Immune Thrombocytopenia: Interim Results From the Phase 4 ADOPT Study

Waleed Ghanima, María Teresa Álvarez Román, María Luisa Lozano, Wolfgang Miesbach, Hafiz Qureshi, Vickie McDonald, Jessica Zhang, Viridiana Cano Garcia, Nina Skuban, María Eva Mingot Castellano

Available materials

• EHA •
• 14 June, 2025 •
• •

Efficacy and safety of avatrombopag for the treatment of pediatric immune thrombocytopenia in the open-label extension of a phase 3, randomized, double-blind, placebo-controlled trial

Rachael F. Grace, Göksel Leblebisatan, Yesim Aydinok, Şule Ünal, John Grainger, Jessica Zhang, Liza Alkhori Franzén, Nina Skuban

Available materials

• EHA •
• 14 June, 2025 •
• •

Real-World Treatment Patterns & Clinical Outcomes in Thrombopoietin Receptor Agonist Naive Patients With Immune Thrombocytopenia Treated With Avatrombopag: Interim Results From the REAL-AVA 3.0 Study

Sandhya Panch, Abiola Oladapo, Scott Kolodny, Michael Vredenburg , Sarah Lucht, Emily Bland, Prathamesh Pathak, Bruce Feinberg, Debbie Jiang

Available materials

• EHA •
• 14 June, 2025 •
• •

Response to Avatrombopag Among Patients with Chronic and Persistent Primary Immune Thrombocytopenia: the REAL-AVA 2.0 Real-World Study

Moshe Y Levy, Shruti Chaturvedi, Scott Kolodny, Abiola Oladapo, Chelsea Bernheisel, Elyse Swallow, Debbie Goldschmidt, Alexandra Greatsinger, Loren Ormenaj, Sinia Sareen, Michael Vredenburg , Srikanth Nagalla

Available materials

• EHA •
• 14 June, 2025 •
• •

Evaluation of Efficacy and Safety of Avatrombopag in Children with Immune Thrombocytopenia based on Disease Duration: Results from the Avatrombopag Phase 3-b Pediatric Trial

Rachael F. Grace, Göksel Leblebisatan, Yesim Aydinok, Şule Ünal, John Grainger, Amanda Grimes, Michele Lambert, Jessica Zhang, Brian D. Jamieson, Michael Vredenburg , Scott Kolodny

Available materials

• EHA •
• 13 June, 2025 •
• •

Durability of Response to Avatrombopag Among Patients with Primary Immune Thrombocytopenia: The REAL-AVA 2.0 Real-World Study

Srikanth Nagalla, Moshe Y Levy, Shruti Chaturvedi, Scott Kolodny, Abiola Oladapo, Chelsea Bernheisel, Elyse Swallow, Debbie Goldschmidt, Alexandra Greatsinger, Loren Ormenaj, Sinia Sareen, Michael Vredenburg

Available materials

• EHA •
• 13 June, 2025 •
• •

Clinically Meaningful Response to Avatrombopag: A Phase 3B Trial for Treatment of Children with ITP

Rachael F. Grace, Göksel Leblebisatan, Yesim Aydinok, Şule Ünal, John Grainger, Amanda Grimes, Michele Lambert, Jessica Zhang, Brian Jamieson, Michael Vredenburg , Scott Kolodny

Available materials

• EHA •
• 13 June, 2025 •
• •

Platelet Response to Avatrombopag Among Patients with Primary Immune Thrombocytopenia Who Switched from Eltrombopag or Romiplostim: the REAL-AVA 2.0 Real-World Study

Shruti Chaturvedi, Moshe Y Levy, Scott Kolodny, Abiola Oladapo, Chelsea Bernheisel, Elyse Swallow, Debbie Goldschmidt, Alexandra Greatsinger, Loren Ormenaj, Sinia Sareen, Michael Vredenburg , Srikanth Nagalla

Available materials

• EHA •
• 13 June, 2025 •
• •

Interim analysis of the ongoing COMPLETE study on the real-world effectiveness of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria (PNH)

Régis Peffault de Latour, Roochi Trikha, Lenka Mastíková, Carmen Gonzalez Gonzalez, Håkan Malmström, Stefan Lethagen

Available materials

• EHA •
• 13 June, 2025 •
• •

Transfusion-related cost and time burden offsets in patients with myelofibrosis treated with pacritinib compared to best available therapy based on PERSIST-2 trial

Abiola Oladapo, Karisse Roman-Torres, Aaron T Gerds, Stephen T. Oh

Available materials

• EHA •
• 13 June, 2025 •
• •

Efficacy of pacritinib vs momelotinib in patients with thrombocytopenic MF: a matched adjusted indicated treatment comparison

Naveen Pemmaraju, Alessandro Lucchesi, Stephen T. Oh, Koo Wilson, Zalmai Hakimi, Sarah A. Buckley, Mikolaj Parkitny, Piotr Wojciechowski, Klaudia Kolonko, John O. Mascarenhas

Available materials

• EHA •
• 13 June, 2025 •
• •

Hematologic improvement experienced by pacritinib-treated patients with myelofibrosis in real-world clinical settings

Michael Marrone, Samantha Eiffert, Lisa Morere, Abiola Oladapo, Anubhav Sharma, Purvi Suthar, Anupama Vasudevan, Michael Vredenburg , Raajit Rampal, John Mascarenhas

Available materials

• EHA •
• 13 June, 2025 •
• •

Early response in complement inhibitor naïve patients with paroxysmal nocturnal hemoglobinuria treated with pegcetacoplan in the Phase 3 PRINCE trial

Austin G. Kulasekararaj, Elena Solomou, Christopher Patriquin, Peter Hillmen, Sheena Patel, Johan Szamosi, Elena Surova, Alexander Röth

Available materials

• EHA •
• 12 June, 2025 •
• •

Emapalumab in patients with primary hemophagocytic lymphohistiocytosis: Efficacy and safety outcomes from a multinational, open-label, single-arm study

Franco Locatelli, Ahmed Naqvi, Beki James, Julián Sevilla, Simone Cesaro, Stephan Ehl, Didier Halimi, Emmanuel Monnet, Ben Peace, Veronica Asnaghi, Cristina de Min, Michael Jordan

Available materials

• EHA •
• 12 June, 2025 •
• •

Cytopenia is associated with real-world disease progression and diminished survival in patients with myelofibrosis: Analysis of a US national administrative claims database

Lindsay AM Rein, Nicole M Engel-Nitz, Michael Marrone, Jefferey McPheeters, Abiola Oladapo, Purvi Suthar, Michael Vredenburg , Yong Zhu, Aaron T Gerds, Lucia Masarova